Geron intends to divest stem cell programs to BioTime; finalized
Geron Corp. (developing oncology therapeutics) signed a non-binding letter of intent to divest to stem cell technology firm BioTime Inc.’s newly established BioTime Acquisition Corp. (BAC) IP and assets covering its human embryonic stem cell programs.
- Gene Therapy, Cell Therapy
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- Product Purchase
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.